Skip to main content
S. 775 118th Congress Senate

Increasing Transparency in Generic Drug Applications Act

Official title: A bill to provide for increased transparency in generic drug applications.

Introduced: April 25, 2023 Introduced by: Margaret Wood Hassan Democratic · New Hampshire See on congress.gov
Health Administrative law and regulatory proceduresDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationPrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 14, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Mar 14, 2023
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action March 14, 2023

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Plain-English summary Congressional Research Service

Increasing Transparency in Generic Drug Applications Act

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

 Related & companion bills 4
  • HR 3561 PATIENT Act of 2023
  • S 1114 Expanding Access to Low-Cost Generics Act of 2023
  • HR 3839 To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
  • HR 5378 Lower Costs, More Transparency Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 22

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 22 filings →
 Cosponsors 2
All 2 Democratic 1 Republican 1
D
Hickenlooper, John W.
Colorado · Apr 25, 2023
 R
Paul, Rand
Kentucky · Mar 14, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). S. 775: Increasing Transparency in Generic Drug Applications Act. 118th Congress. Open America. https://openamerica.io/bill/118-S-775/
MLA
"S. 775: Increasing Transparency in Generic Drug Applications Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-775/.
Bluebook (legal)
S. 775, 118th Cong. (2026), https://openamerica.io/bill/118-S-775/.
Markdown link
[S. 775: Increasing Transparency in Generic Drug Applications Act](https://openamerica.io/bill/118-S-775/)
Report a problem